The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Pyxis Oncology Inc (NASDAQ: PYXS) was $3.66 for the day, up 13.31% from the previous closing price of $3.23. In other words, the price has increased by $13.31 from its previous closing price. On the day, 0.88 million shares were traded. PYXS stock price reached its highest trading level at $3.67 during the session, while it also had its lowest trading level at $3.25.
Ratios:
Our analysis of PYXS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $5.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.Stephens initiated its Overweight rating on November 08, 2024, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 226986384 and an Enterprise Value of 157504368. For the stock, the TTM Price-to-Sale (P/S) ratio is 80.49 while its Price-to-Book (P/B) ratio in mrq is 2.59. Its current Enterprise Value per Revenue stands at 55.853 whereas that against EBITDA is -1.956.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.26, which has changed by 0.0 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 90.57%, while the 200-Day Moving Average is calculated to be 161.81%.
Shares Statistics:
PYXS traded an average of 674.18K shares per day over the past three months and 1119230 shares per day over the past ten days. A total of 62.02M shares are outstanding, with a floating share count of 44.14M. Insiders hold about 28.82% of the company’s shares, while institutions hold 34.80% stake in the company. Shares short for PYXS as of 1759190400 were 4131340 with a Short Ratio of 6.13, compared to 1756425600 on 4334176. Therefore, it implies a Short% of Shares Outstanding of 4131340 and a Short% of Float of 8.06.
Earnings Estimates
The stock of Pyxis Oncology Inc (PYXS) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.14 and -$1.42 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$1.17, with 7.0 analysts recommending between -$0.78 and -$1.42.
